Stereotactic body radiotherapy plus lenvatinib and sintilimab with and without transarterial embolization for advanced hepatocellular carcinoma with portal vein tumor thrombus: a dual-center, propensity score-matched retrospective analysis
Adding TAE to SBRT, lenvatinib, and sintilimab prolonged the median PFS in patients with advanced HCC and PVTT, showing comparable safety. This real-world study supports dual LRT combined with targeted immunotherapy as a feasible treatment option and merits prospective validation.
Authors
- Xinmu Zhang (ORCID: https://orcid.org/0009-0002-0330-6008)
- Quan Wang (ORCID: https://orcid.org/0000-0003-4997-7173)
- Taifeng Zhu (ORCID: https://orcid.org/0009-0009-0320-1936)
- Haitao Zhao
- Xuezhang Duan
- Jun Jia
- Jing Sun
- Duo Li
- Cong Ning
Institutions
- Chinese Academy of Medical Sciences & Peking Union Medical College (CN)
- Peking Union Medical College Hospital (CN)
- Chinese PLA General Hospital (CN)
Publication Details
- Journal
- Frontiers in Immunology
- Published
- 2026-03-04
- DOI
- https://doi.org/10.3389/fimmu.2026.1644027
- Primary Topic
- Hepatocellular Carcinoma Treatment and Prognosis
- Type
- article
- Field-Weighted Citation Impact
- 0.00